Optical coherence tomography: Limits of the retinal-mapping program in age-related macular degeneration

British Journal of Ophthalmology

Volumn 92, Issue 7, 2008, Pages 933-935

  Krebs, I ^a,b,c   Haas, P ^a,b   Zeiler, F ^a,b   Binder, S ^a,b  

^a Department of Ophthalmology Rudolf Foundation Clinic ^*  (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EYE EXAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR FIBROSIS; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MACULAR DEGENERATION; MALE; MIDDLE AGED; PIGMENT EPITHELIUM OF EYE; RETINA; RETROSPECTIVE STUDIES; SOFTWARE; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 47049106131     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.128447     Document Type: Article

References (20)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-45.
2. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207.
3. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
4. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.
5. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508.e1-25.
6. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103:1260-70.
7. Puliafito CA, Hee MR, Lin CP, et al. Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217-29.
8. Holz FG, Jorzik J, Schutt F, et al. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 2003;110:400-5.
9. Koozekanani D, Roberts C, Katz SE, et al. Intercession repeatability of macular thickness measurements with the Humphrey 2000 OCT. Invest Ophthalmol Vis Sci 2000;41:1486-91.
10. Massin P, Vicaut E, Haouchine B, et al. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001;119:1135-42.
11. Kaiser PK, BIodi BA, Shapiro H, Acharya NR, MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75.
12. Joeres S, Kaplowitz K, Brubaker JW, et al. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Ophthalmology 2008;115:347-354.e2.
13. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007;143:510-2.
14. Sadda SR, Wu Z, Walsh AC, et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2006;113:285-93.
15. Ray R, Stinnett SS, Jaffe GJ. Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol 2005;139:18-29.
16. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45:2399-406.
17. Hee MR. Automated measurements of retinal thickness with optical coherence tomography. Am J Ophthalmol 2005;140:350-1.
18. Sadda SR, Joeres S, Wu Z, et al. Error correction and quantitative subanalysis of optical coherence tomography data using computer-assisted grading. Invest Ophthalmol Vis Sci 2007;48:839- 48.
19. Leung CK, Chan WM, Chong KK, et al. Alignment artifacts in optical coherence tomography analyzed images. Ophthalmology 2007;114:263-70.
20. Ko TH, Fujimoto JG, Schuman JS, et al. Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. Ophthalmology 2005;112:1922.e1-15.